1	Developing an Individualized Clinical Prediction Rules of Antihypertensive Drugs: A Study
2	Protocol Based on Real-world Practice
3	
4	Dongsheng Hong <sup>1, 2</sup> ; Wendan Shi <sup>3</sup> ; Xiaoyang Lu <sup>1</sup> ; Wu Jiaying <sup>1</sup> ; Yan Lou <sup>1*</sup> ; Lu Li <sup>2*</sup>
5	
6	<sup>1</sup> Department of Pharmacy of the First Affiliated Hospital, Zhejiang University School of
7	Medicine, Hangzhou, Zhejiang Province, China.
8	<sup>2</sup> Department of Social Medicine, Zhejiang University School of Medicine, Hangzhou, Zhejiang
9	Province, China.
10	<sup>3</sup> Sydney Nursing School, Faculty of Medicine and Health, the University of Sydney, Australia.
11	
12	* is the corresponding author, Tel/Fax: 86-571-87232221; E-mail: yanlou@zju.edu.cn; E-mail:
13	lilu@zju.edu.cn
14	
15	
16	
17	
18	
19	
20	

Abstract

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

**Background:** Hypertension is one of the most urgent public health challenges, and drug therapy is the primary method to control blood pressure for patients. However, blood pressure control rate is still poor with antihypertensive drugs use. Although Clinical Prediction Rules (CPR) is useful to help clinicians make more appropriate decisions at the point of medication, the evidence is still limited in china. The objective of this study is to develop an CPR of antihypertensive drugs in individualized application of patients based on real-world practice. **Methods:** A two-way cohort study has been conducted in one China's large tertiary hospital using clinical information on patient characteristics, drug use and clinical outcome. Data extraction is through ICD-10 disease codes of hypertension from Electronic Medical Record System. Eligible patients admitted from September 2016 to August 2018 who have received at least one antihypertensive drug therapy is included. Patients were grouped into several exposure groups according to medications. COX regression model and clinical specialty survey is applied to identify Influencing Factors (IF) in different study groups, and the discriminant model was used to construct a CPR according IF. The accuracy of the CPR is analyzed by sensitivity, specificity, Youden's index and Receiver Operating Characteristic (ROC) curve. **Discussion:** Result is expected to provide valuable CPR for physicians and policymakers with respect to treating hypertension according characteristic of individual patients. By developing a predictive method for clinical outcomes and treatment costs of antihypertensive medication, we expect to discriminate those patients who would profit from specific scheme of antihypertensive drugs to minimal incidence probability of costs and complications in region of china.

**Trial registration:** This study was registered at www.chictr.org as a primary register of the WHO International Clinical Trials Registry Platform (ICTRP), and the registered number is ChiCTR1900026339. **Keywords:** Clinical Prediction Rules; Decision support; Hypertension; Medical treatment; Medication optimization 

**Highlights** Although Clinical Prediction Rules (CPR) could recognize individual patient risk and help clinicians to make more appropriate decision at the point of medication as part of clinical decision support systems, the evidence in this respect is still limited in China. This study is first going to construct the CPR of multiple antihypertensive drugs in real world practice of China. The highlights of this study is aimed to provide a pragmatic method to support clinical decisions for patients who has received antihypertensive drugs before long-term diagnosis of hypertension in real world practice according to their characteristics that are accessible to clinicians.

# 1. Background

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

Hypertension is one of the constantly rising global health concerns<sup>1, 2</sup>, and it is considered as the enormous sponsor to the burden of disease<sup>3</sup>. In China, there are 270 million adults in total who suffered from a condition of hypertension, the Disability-Adjusted Life Year (DALY) has reached 37.94 million people per year<sup>4</sup>. The direct medical expenses for drug treatment are nearly 40 billion Chinese yuan per year, and it is still increasing accordingly<sup>5</sup>. Under such high medical expenditures, the control rate of Blood Pressure (BP) in China is only 16.9%<sup>5</sup>. With the aging population, changes in lifestyle, and population growth<sup>6</sup>, the burden of illness with hypertension is also growing over time. Drug therapy is currently recognized as the primary method of hypertension treatment<sup>7</sup>. However, hypertension is normally an asymptomatic disease<sup>8</sup>. Patients may suffer from side effects of antihypertensive drugs (AHD), which bring about them become worse than they did before using medication. The poor personal response to standard treatment is one of the main reason of low rate of hypertension control<sup>6</sup>, and a large meta-analysis of prospective study stated the relationship between poor personal response (BP levels) and cardiac-cerebral vascular events<sup>9</sup>. To obtain the maximum antihypertensive effect of existing drugs, physicians and policymakers have turned to the rational use of antihypertensive drugs according to the characteristics of individual patient <sup>10, 11</sup>. Although Clinical Decision Support Systems (CDSS) could be effective in providing an appropriate and cost-effective methods to improve the blood pressure control rate with reducing cardiovascular risk<sup>12, 13</sup>. The evidence of CDSS is from clinical guidelines, which major advocate evidence-based recommend and basically use a standard of universal treatment at the population levels<sup>14</sup>, are not highly concern to the characteristics of individual patients. Otherwise, AHD is

more than 100 varieties in China that may have differences in terms of mechanism of action, dosage, adverse reactions and contraindications. The ability of an individual physician to optimize drug combinations for personal patient is rapidly going beyond their capabilities and comprehension<sup>15</sup>. Therefore, the clinical application of AHD should oblige to be person-centered for individual patients. It should balance of clinical effects, adverse reactions, and costs of treatment, in order to deduce which AHD will have the most effectiveness to control BP at an individual level with a good profile.

Clinical prediction rules (CPR) as an important component of CDSS, which is focusing particularly on the possible applications of individual characteristics for the evaluation risk of hypertensive patients. However, the evidence of CPR is still poor based on clinical feedback. Accordingly, the aim of this study is to eventually provide evidence of developing an CPR to identify of personal clinical characteristics that will better manage the AHD choice to improve disease control of the individual patient and overall hypertension population.

### 2. Methods

### 2.1 Study design

This research will conduct a two-way cohort study of hypertensive patients at the First Affiliated Hospital of College of Medicine of Zhejiang University in China (FHMZC), where the outpatient volume is moreover three million per year as China regional medical center. The information of Patient's treatment outcomes will be collected prospectively in future, and the participants will be grouped according to their exposure at the time of recruitment. Exposure options are first-line treatment drugs according guidelines for hypertension in China<sup>16, 17</sup>, including Angiotensin-Converting Enzyme Inhibitor (ACEI), Angiotensin Receptor Blocker (ARB), Calcium Channel Blockers (CCB), diuretic, and β-blocker used as alone or in

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

combination. This study will follow the statement of Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), and The STROBE Statement Checklist of cohort studies is shown in online supplementary appendix 1. The study period is planned to be over a 3-year period from 1 September 2016 to 31 August 2018. This period has been selected based on the availability of enough patients who would have been exposed to the study hypertensive drugs as well as coinciding with the availability of Electronic Medical Record System (EMRC). 2.2 Study cohort The source patients include all EMRC patients aged 18 years and over, who has diagnosed with hypertension. Antihypertensive drugs exposure will be defined from dispensed prescription records of EMRC, beginning from 1 September 2016 and until the end of study. New patients using antihypertensive drugs will be determined by using a review observation period of 6 months prior to the index prescription date, and which must indicate no hypertensive drugs use during that period. The index date will be identified as the date of the new prescription for antihypertensive drugs. The group of study cohort would be constructed according to the antihypertensive drugs. 2.3 Data extraction The study obtains data through data extraction of EMRC and follow-up survey. Data extraction will through ICD-10 disease codes<sup>18</sup>, including I10.X00, I10.X01, I10.X02, I10.X03, I10.X04, I10.X05, I10.X06, I11.900, I12.903 and I15.000. Information will be collected as the following: (1) demographic information; (2) medical history; (3) duration of illness; (4) underlying diseases; (5) medication history; (6) alcohol intake/smoking history; (7) inspection information; (8) efficacy evaluation; (9) complications.

# 2.4 Sample size

The sample size of our study is estimated by 10-15 times of the total factor<sup>19</sup>. If the factor involved is 30 temporarily, the sample size should be no less than 300 cases for a group. In addition, assuming that the loss rate of cohort study is 20%, the sample size should be further expanded to no less than 375 cases for a group. If the model is constructed according to 375 cases and verified by 375 cases, the final requirement is that the sample size should be enlarged to no less than 750 cases for a group.

## 2.5 Cost assignments and Outcomes measures

Direct costs will be assigned in Chinese Yuan (¥) using EMRC, and the costs is classified into two categories with drug related and costs for medical services. All major outcomes are identified: (1) coronary artery disease, (2) chronic heart failure, (3) renal insufficiency, and (4) cerebrovascular disease<sup>20</sup>.

### 2.6 Identification of influencing factors

Data characteristics among patients are commonly believed to be associated with treatment response and outcomes, and disease progression. We will conduct a method of COX regression and clinical specialty survey to identify Influencing Factors (IF) in different study groups of cohort<sup>21</sup>.

### 2.7 Individualized Clinical Prediction Rules

IF are directly related to medication in patients with hypertension. The discriminant model will be utilized to construct an individualized CPR based on the clinical outcomes and IF, and the clinical outcomes include the cost of treatment and the main outcomes as defined before<sup>22</sup>. The accuracy of the rules is analyzed by sensitivity, specificity, Youden's index and Receiver Operating Characteristic (ROC) curve<sup>23-25</sup>.

The real-time data of each stage of patients are input into CPR to calculate the treatment cost of different medication schemes and their impact on the treatment outcome of patients under the current condition of exporting patients, so as to assist physicians in choosing Medication drugs for hypertension.

### 2.8 Statistical analysis

The measurement data of normal distribution are expressed by M (Q<sub>R</sub>), the classification data is worked out by relative number, the comparison of continuous variables is analyzed by t-test, the classification variables is calculated by chi-square test, the survival analysis between groups is performed by Kaplan-Meier survival curve and log rank test, and the multivariate analysis is done by Cox regression. The risk grade of hypertension complications was judged by the Risk Ratio (RR) of different medication schemes<sup>26, 27</sup>. If RR is ranged from 1.2-1.5, the risk factors are indicated with a weak relationship to complications, while an RR of 1.6-2.9 shows moderate relationship to, and an RR of 3.0 and above illustrates strong relationship to the complications. Besides, the accuracy of risk estimation is judged by the 95% Confidence Interval (CI) of RR. Data analysis was carried out by R software (Version 3.5.2, https://www.r-project.org/).

### 3. Discussion

Artificial intelligence (AI) is developing rapidly in field medic of china, and CDSS is a typical representative. CPR is a core part of CDSS, which stand for a method of recognizing individual patient of cost and effectiveness to help policymakers make more appropriate decisions at the point of medication<sup>28, 29</sup>. Although CPR is important in antihypertensive drugs, the evidence in this respect is still limited in region of China.

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

To our knowledge, this trial is a first real-world study in China, in which the occurrence of clinical outcomes and medication costs in patients with antihypertensive drugs will be recorded and the relationship between cost-effectiveness of medication and patient characteristics/ therapeutic schedule will be evaluated based on real-world practice. In fact, it has increased its awareness among physicians to provide effective antihypertensive drug scheme according to patient characteristics. Our study will address drug treatment for hypertension in Chinese healthcare facilities, with a particular focus on tertiary hospitals, from a range of real-world perspectives. As a result, we will construct a two-way study cohort according AHD, and the data of each group include socio-demographic characteristics, disease progression, and clinical outcome<sup>30, 31</sup>. The COX regression model and clinical specialty survey are carried out to identified IF in different study cohorts<sup>21</sup>, and the discriminant model will be used to develop CPR<sup>22</sup>. To evaluate the effect of different medication regimens and patient characteristics on clinical outcomes according to CPR, and the physicians reasonably choose the medication plan according to the evaluation results. The present analysis is subject to some limitations intrinsic to real world studies, including potential confounding factors<sup>32</sup> such as polydrug use among users of antihypertensive drugs<sup>33, 34</sup>, adherence to medication<sup>34</sup>, and indication bias<sup>35</sup> among patients with hypertension. We attempted to minimize these by recruiting the predominant individuals using antihypertensive drugs as the drug of choice within the past six months prior to enrollment to the study. Importantly, it is noted that the emphasis of the study is a pragmatic approach to clinical decision support for patients who must be accept antihypertensive drugs before long diagnosis of

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

hypertension in real world practice according patient characteristics that are accessible to physicians. In summary, our research findings hope to provide valuable CPR for physicians and policymakers with respect to treating hypertension according characteristic of individual patients. By developing a predictive method for clinical outcomes and treatment costs of antihypertensive medication, we expect to discriminate those patients who would profit from specific scheme of antihypertensive drugs to minimal incidence probability of costs and complications. List of abbreviations **CPR:** Clinical Prediction Rules; **CDSS:** Clinical Decision Support Systems; **AHD:** Antihypertensive drugs (AHD); AI: Artificial intelligence; IF: Influencing Factors; EMRC: Electronic Medical Record System; **DALY:** Disability-Adjusted Life Year **Declarations** Ethics approval and consent to participate Required ethics approvals have been obtained prior to our study from the ethics committee of the First Affiliated Hospital of College of Medicine of Zhejiang University in China, and the committee's reference number is #2019-1391. **Ethics and consent to participate** This study conduct by using previously obtained information, and meet four conditions at the same time, including "It is unrealistic or impossible to obtain informed consent", "The Privacy of subject could be well protected", "Not more than the minimum risk" and "The right and interests of subject will not be invaded". Therefore, after careful ethical review by the ethics committee, this study was approved Informed Consent Waiver (Reference number is #2019-1391).

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

Availability of data and materials The datasets used and/or analysis during the current study are available from the corresponding author on reasonable request. **Competing interests** The authors declare that they have no competing interests. **Funding** Not applicable. **Authors' contributions** DSH and YL had the original idea for this study. WDS and JYW reviewed previous studies. XYL interpreted the patient data regarding antihypertensive drugs. XYL and LL Provide statistical support. DHS registered in chictr and is the guarantor of the protocol. All authors read and approved the final version of the article. Acknowledgments This study is supported by the Zhejiang Province Key Research and Development Program (2019C04006) and Zhejiang Provincial Natural Science Foundation (LQ20G030025) of China. Not applicable. **Trial registration:** This study was registered at www.chictr.org as a primary register of the WHO International Clinical Trials Registry Platform (ICTRP), and the registered number is ChiCTR1900026339.

### Reference

273

- 1. Monticone S, D'Ascenzo F, Moretti C, et al. Cardiovascular events and target organ damage in
- 275 primary aldosteronism compared with essential hypertension: a systematic review and meta-
- analysis. The lancet Diabetes & endocrinology 2018; 6(1): 41-50.
- 2. Beaney T, Schutte AE, Tomaszewski M, et al. May Measurement Month 2017: an analysis of
- blood pressure screening results worldwide. *The Lancet Global health* 2018; 6(7): e736-e43.
- 3. Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China:
- current features and implications. *Nature reviews Cardiology* 2019; 16(4): 203-12.
- 4. Mendis S, Davis S, Norrving B. Organizational update: the world health organization global
- status report on noncommunicable diseases 2014; one more landmark step in the combat against
- 283 stroke and vascular disease. *Stroke* 2015; 46(5): e121-2.
- 5. Zhang HY, Jian WY, Fang H. [Analysis of substitutional effect of outpatient expenditure on
- inpatient expenditure in hypertensive patients with rural new cooperative medical scheme.
- 286 *Beijing da xue xue bao Yi xue ban = Journal of Peking University Health sciences* 2016; 48(3):
- 287 472-7.
- 6. Lobo MD, Sobotka PA, Pathak A. Interventional procedures and future drug therapy for
- 289 hypertension. *European heart journal* 2017; 38(15): 1101-1111.
- 7. Flack JM, Adekola B. Blood pressure and the new ACC/AHA hypertension guidelines. *Trends*
- in cardiovascular medicine 2019.
- 8. Thomson P, Dowding D, Swanson V, et al. A computerised guidance tree (decision aid) for
- 293 hypertension, based on decision analysis: development and preliminary evaluation. *European*
- journal of cardiovascular nursing: journal of the Working Group on Cardiovascular Nursing of
- the European Society of Cardiology 2006; 5(2): 146-9.
- 9. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-specific
- relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for
- one million adults in 61 prospective studies. *Lancet* 2002; 360(9349): 1903-13.

- 10. Verheijen RB, Beijnen JH, Schellens JHM, Huitema ADR, Steeghs N. Clinical
- 300 Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. Clinical
- 301 *pharmacokinetics* 2017; 56(9): 987-97.
- 11. Yannoutsos A, Kheder-Elfekih R, Halimi JM, Safar ME, Blacher J. Should blood pressure
- 303 goal be individualized in hypertensive patients? *Pharmacological research* 2017; 118: 53-63.
- 12. Anchala R, Kaptoge S, Pant H, Di Angelantonio E, Franco OH, Prabhakaran D. Evaluation
- of effectiveness and cost-effectiveness of a clinical decision support system in managing
- 306 hypertension in resource constrained primary health care settings: results from a cluster
- randomized trial. *Journal of the American Heart Association* 2015; 4(1): e001213.
- 308 13. Van de Velde S, Heselmans A, Delvaux N, et al. A systematic review of trials evaluating
- success factors of interventions with computerised clinical decision support. *Implementation*
- 310 *science : IS* 2018; 13(1): 114.
- 311 14. Savoia C, Volpe M, Grassi G, Borghi C, Agabiti Rosei E, Touyz RM. Personalized
- medicine-a modern approach for the diagnosis and management of hypertension. *Clinical*
- 313 *science* 2017; 131(22): 2671-85.
- 314 15. Tsigelny IF. Artificial intelligence in drug combination therapy. *Briefings in bioinformatics*
- 315 2019; 20(4):1434-1448.
- 16. Joint Committee for Guideline R. 2018 Chinese Guidelines for Prevention and Treatment of
- 317 Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and
- 318 Treatment of Hypertension. *Journal of geriatric cardiology* 2019; 16(3): 182-241.
- 17. Muntner P, Carey RM, Gidding S, et al. Potential US Population Impact of the 2017
- ACC/AHA High Blood Pressure Guideline. *Circulation* 2018; 137(2): 109-18.
- 18. Hirsch JA, Nicola G, McGinty G, et al. ICD-10: History and Context. AJNR American
- *journal of neuroradiology* 2016; 37(4): 596-9.

- 19. Riley RD, Snell KI, Ensor J, et al. Minimum sample size for developing a multivariable
- prediction model: PART II binary and time-to-event outcomes. Statistics in medicine 2019;
- 325 38(7): 1276-96.
- 326 20. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular
- and renal outcomes: updated systematic review and meta-analysis. *Lancet* 2016; 387(10017):
- 328 435-43.
- 329 21. Scosyrev E, Glimm E. Power analysis for multivariable Cox regression models. Statistics in
- 330 *medicine* 2019; 38(1): 88-99.
- 22. de Souza Vieira EE, Bispo JAM, Silveira L, Jr., Fernandes AB. Discrimination model
- applied to urinalysis of patients with diabetes and hypertension aiming at diagnosis of chronic
- kidney disease by Raman spectroscopy. *Lasers in medical science* 2017; 32(7): 1605-13.
- 334 23. Hajian-Tilaki K. The choice of methods in determining the optimal cut-off value for
- quantitative diagnostic test evaluation. *Statistical methods in medical research* 2018; 27(8):
- 336 2374-83.
- 24. Wu M, Shu Y, Li Z, Liu A. Repeated significance tests of linear combinations of sensitivity
- and specificity of a diagnostic biomarker. *Statistics in medicine* 2016; 35(19): 3397-412.
- 25. Grunkemeier GL, Jin R. Receiver operating characteristic curve analysis of clinical risk
- models. *The Annals of thoracic surgery* 2001; 72(2): 323-6.
- 341 26. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort
- studies of common outcomes. *Jama* 1998; 280(19): 1690-1.
- 27. Tripepi G, Jager KJ, Dekker FW, Wanner C, Zoccali C. Measures of effect: relative risks,
- odds ratios, risk difference, and 'number needed to treat'. *Kidney international* 2007; 72(7): 789-
- 345 91.
- 28. Feldstein DA, Hess R, McGinn T, et al. Design and implementation of electronic health
- record integrated clinical prediction rules (iCPR): a randomized trial in diverse primary care
- settings. *Implementation science : IS* 2017; 12(1): 37.

- 349 29. Michie S, Thomas J, Johnston M, et al. The Human Behaviour-Change Project: harnessing
- 350 the power of artificial intelligence and machine learning for evidence synthesis and interpretation.
- 351 *Implementation science : IS* 2017; 12(1): 121.
- 30. Attaei MW, Khatib R, McKee M, et al. Availability and affordability of blood pressure-
- lowering medicines and the effect on blood pressure control in high-income, middle-income, and
- low-income countries: an analysis of the PURE study data. *The Lancet Public health* 2017; 2(9):
- 355 e411-e9.
- 31. Chen S, Sudharsanan N, Huang F, Liu Y, Geldsetzer P, Barnighausen T. Impact of
- community based screening for hypertension on blood pressure after two years: regression
- discontinuity analysis in a national cohort of older adults in China. *Bmj* 2019; 366: 14064.
- 32. Geerligs L, Rankin NM, Shepherd HL, Butow P. Hospital-based interventions: a systematic
- review of staff-reported barriers and facilitators to implementation processes. *Implementation*
- 361 *science : IS* 2018; 13(1): 36.
- 33. Sabido M, Hohenberger T, Grassi G. Pharmacological intervention in hypertension using
- beta-blockers: Real-world evidence for long-term effectiveness. *Pharmacological research* 2018;
- 364 130: 191-7.
- 34. Verma AA, Khuu W, Tadrous M, Gomes T, Mamdani MM. Fixed-dose combination
- antihypertensive medications, adherence, and clinical outcomes: A population-based
- retrospective cohort study. *PLoS medicine* 2018; 15(6): e1002584.
- 35. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of
- cardiovascular disease and death: a systematic review and meta-analysis. *Lancet* 2016;
- 370 387(10022): 957-67.